Sorrento Therapeutics Ink. (Seite 64)

[diehoffungstirbtzuletzt]

Kann ruhig so weiter wandern

[Charly_2]

Brasilien
https://www.einnews.com/pr_news/543176460/brazilian-approval…

[diehoffungstirbtzuletzt]

Muss doch langsam mal in alte Höhen laufen

[Charly_2]

Ne Ansage
https://www.google.com/amp/s/m.investing.com/news/hc-wainwri…

[Charly_2]

Schon früher gepostet, aktualisiert, ohne Gewähr auf Vollständigkeit

Nach der letzte Woche gemeldeten ACEA Übernahme (1.06.21) hat Sorrento mehr als 60 Positionen in klinischen Programmen:

Phase 3, close to EUA or close to market (12 programs)
1. Abivirtinib NSCLC NDA filed China
2. Abivirtinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar
7. SP-102 sciatica
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application
11. Covi-Trace EUA application
12. Cynviloq (part of PSS lawsuit $1B, settled 22. July 21)

Phase 2 (12 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential
4. Covi-Track EUA pre-validation
5. PD-L1 partnered
6. Herceptin delivery partnered
7. Abivirtinib Lymphoma
8. Abivirtinib Covid 19
9. Abivirtinib prostate cancer ph.2 IND
10. Abivirtinib Lupus ph.2 IND
11. Abivirtinib hairy cell leukemia
12. CD47 partnered

Phase 1, IND filed or pre-IND (37+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T IND
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding, US Army
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Covi-Drops ph.1
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 pre-IND partnered
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. 1,000,000+ small molecule library
36. Ten quadrillion antibody library
37. STI Sofusa-1003 ph. 1b

Beteiligungen:
-8.2 million shares of ImmunityBio
-20 million shares of Celularity
-35% of Immune Oncia

EUA erteilt am 2.06.21: COVI-STIX für Mexico, Eigenproduktion durch Sorrento

[Charly_2]

Antwort auf Beitrag Nr.: 68.411.480 von Weisbart am 04.06.21 21:54:46

Zitat von Weisbart: Sie nerven diese ganzen Pinscher und Kleingeister in dieser Aktie. Kaum kauft mal jemand eine größere Tüte Aktien , verscherbeln die Angsthasen Ihren Anteil für einen kleinen, sehr kleinen schnellen Gewinn.

Stimmt, müsste demnext besser werden, wenn die Amis die $1’400 von Biden bei ihren Billigst-Brokern an der Börse verscherbelt haben

[Weisbart]

Sie nerven diese ganzen Pinscher und Kleingeister in dieser Aktie. Kaum kauft mal jemand eine größere Tüte Aktien , verscherbeln die Angsthasen Ihren Anteil für einen kleinen, sehr kleinen schnellen Gewinn. ☹️

[diehoffungstirbtzuletzt]

Wird ja langsam 👍

[Magnetfeldfredy]

Sorrento hat eine Mega-Pipline und zudem echte Chancen für Heilmittel gegen Covid, das kann meine nächste Novavax werden, Tenbagger:

Why Sorrento Therapeutics Stock Surged Today
The biotech could play an important role in the battle against cancer and autoimmune diseases.
Joe Tenebruso
(TMFGuardian)
Jun 2, 2021 at 4:54PM
Author Bio
What happened

Shares of Sorrento Therapeutics (NASDAQ:SRNE) jumped 10.5% on Wednesday, as investors cheered two positive announcements from the biopharmaceutical company.
So what

Sorrento said it completed its acquisition of ACEA Therapeutics for roughly $38 million, as well as up to $450 million in additional payments if certain regulatory approvals and sales goals are met. Sorrento praised the drugmaker's pipeline, which includes abivertinib, which has generated promising clinical trial results in lymphoma and non-small cell lung cancer.

Abivertinib is also being evaluated in phase 2 clinical trials for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19. Sorrento said it expects to share the results from this trial by late September.
People are working in a lab.

Image source: Getty Images.

Separately, Sorrento announced that the Mexican government added Covi-Stix to its official list of rapid antigen tests approved for emergency use in the country. Sorrento's approximately 15-minute diagnostic test outperformed other COVID-19 tests for both sensitivity and specificity in studies conducted by Mexican health officials.

The designation will now allow Sorrento to begin marketing Covi-Stix in Mexico. It could also help the biotech gain additional emergency use authorizations in other Latin American countries, according to management.
Now what

Sorrento intends to begin new clinical trials for abivertinib for the treatment of other cancers and autoimmune diseases, including prostate cancer, leukemia, multiple sclerosis, and lupus. The company is also seeking a larger partner to help co-develop and market abivertinib globally.

[scalabletrade]

Bin long investiert

So viele gute News auf einmal, jetzt darf es gerne Stück für Stück nach oben gehen!

Keine Handelsempfehlung, nur persönliche Meinung